{"id":"oral-vioxx-rofecoxib","safety":{"commonSideEffects":[{"rate":null,"effect":"Cardiovascular thrombotic events (myocardial infarction, stroke)"},{"rate":null,"effect":"Gastrointestinal ulceration and bleeding"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Edema"},{"rate":null,"effect":"Dyspepsia"}]},"_chembl":{"chemblId":"CHEMBL122","moleculeType":"Small molecule","molecularWeight":"314.36"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a COX-2 selective inhibitor, rofecoxib blocks the COX-2 enzyme preferentially over COX-1, thereby reducing inflammatory prostaglandins while theoretically sparing the protective prostaglandins produced by COX-1 in the gastrointestinal tract and kidneys. This selectivity was intended to provide anti-inflammatory and analgesic benefits with a lower risk of gastrointestinal ulceration compared to non-selective NSAIDs.","oneSentence":"Rofecoxib selectively inhibits cyclooxygenase-2 (COX-2), reducing prostaglandin production to decrease inflammation and pain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:24:43.780Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Osteoarthritis"},{"name":"Acute pain"},{"name":"Dysmenorrhea"}]},"trialDetails":[{"nctId":"NCT01762891","phase":"NA","title":"CI(R)CA : Coumadin Interaction With Rofecoxib, Celecoxib and Acetaminophen","status":"COMPLETED","sponsor":"Hospital Universitario Pedro Ernesto","startDate":"2003-03","conditions":"Antiphospholipid Antibody Syndrome","enrollment":22},{"nctId":"NCT00568295","phase":"PHASE3","title":"A Four-Week Study Comparing Acetaminophen Extended Release and Rofecoxib in the Treatment of Osteoarthritis of the Knee","status":"COMPLETED","sponsor":"Johnson & Johnson Consumer and Personal Products Worldwide","startDate":"1999-10","conditions":"Osteoarthritis of the Knee","enrollment":403},{"nctId":"NCT00637949","phase":"PHASE3","title":"Safety of Lumiracoxib in Patients With Osteoarthritis","status":"COMPLETED","sponsor":"Novartis","startDate":"2000-12","conditions":"Osteoarthritis","enrollment":309},{"nctId":"NCT00164892","phase":"PHASE3","title":"Selective COX-II Inhibitor as an Adjuvant Therapy in Patients With Resectable Advanced Stomach Cancer ( Histological Staging ≥ T2N1) - A Multi-Centre Prospective Randomised Controlled Trial","status":"UNKNOWN","sponsor":"Chinese University of Hong Kong","startDate":"2004-10","conditions":"Cancer of Stomach","enrollment":214}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Oral Vioxx (Rofecoxib)","genericName":"Oral Vioxx (Rofecoxib)","companyName":"Chinese University of Hong Kong","companyId":"chinese-university-of-hong-kong","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rofecoxib selectively inhibits cyclooxygenase-2 (COX-2), reducing prostaglandin production to decrease inflammation and pain. Used for Rheumatoid arthritis, Osteoarthritis, Acute pain.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}